Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) EPS (Weighted Average and Diluted) (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$0.12 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 53.85% to -$0.12 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.23, a 12.84% decrease, with the full-year FY2024 number at -$1.19, down 26.6% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.12 for Q3 2025 at Marker Therapeutics, up from -$0.29 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.29 in Q2 2023 to a low of -$5.04 in Q4 2021.
  • A 5-year average of -$0.63 and a median of -$0.29 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 2686.82% in 2021, then surged 363.64% in 2023.
  • Marker Therapeutics' EPS (Weighted Average and Diluted) stood at -$5.04 in 2021, then surged by 71.23% to -$1.45 in 2022, then surged by 77.93% to -$0.32 in 2023, then crashed by 31.25% to -$0.42 in 2024, then soared by 71.43% to -$0.12 in 2025.
  • Per Business Quant, the three most recent readings for MRKR's EPS (Weighted Average and Diluted) are -$0.12 (Q3 2025), -$0.29 (Q2 2025), and -$0.4 (Q1 2025).